The 8 most recent market catalysts affecting $CSL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 25, 2026
Corporate Catalyst
Neutral
Impact 55
DA Davidson Initiates Coverage On Carlisle Companies with Neutral Rating, Announces Price Target of $410
DA Davidson analyst Garik Shmois has initiated coverage on Carlisle Companies (CSL) with a 'Neutral' rating and a price target of $410. This event is significant because new analys…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 85
Carlisle Companies shares are trading higher after the company reported better-than-expected Q2 financial results.
The better-than-expected Q2 financial results for Carlisle Companies (CSL) are a significant positive catalyst, indicating strong operational performance and potentially a healthy …
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 65
Carlisle Companies Increases Full-Year Buyback Target To $1.2B
Carlisle Companies (CSL) has increased its full-year share repurchase target to $1.2 billion. This is a significant capital allocation decision, indicating that management believes…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
Carlisle Companies shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline indicates a significant corporate catalyst for Carlisle Companies (CSL). Better-than-expected financial results typically lead to increased investor confidence, drivi…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 92
Carlisle Companies Q2 Adj. EPS $7.03 Beats $6.35 Estimate, Sales $1.600B Beat $1.476B Estimate
Carlisle Companies (CSL) announced Q2 adjusted EPS of $7.03, surpassing the $6.35 consensus by 10.71%, and sales of $1.600 billion, beating the $1.476 billion estimate by 8.41%. Th…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 65
U.S. FDA Licenses First Freeze-dried Plasma Product Ezplaz In The United States; Ezplaz Available In Group Ab And Group A Low-Titer Anti-B For Emergency Transfusion
The FDA's licensing of Ezplaz, the first freeze-dried plasma product in the U.S., is a significant development for emergency medicine. This product offers a stable, readily availab…
Jul 20, 2026
Corporate Catalyst
Bearish
Impact 75
Carlisle Companies shares are trading lower after Baird lowered its price target from $425 to $405.
The price target reduction from Baird, a reputable financial institution, indicates a revised outlook on Carlisle Companies' future performance or valuation. This directly impacts …
Jul 20, 2026
Corporate Catalyst
Bearish
Impact 55
Baird Maintains Outperform on Carlisle Companies, Lowers Price Target to $405
Baird analyst Timothy Wojs maintained an 'Outperform' rating on Carlisle Companies (CSL) but lowered the price target from $425 to $405. This action signals a slight recalibration …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.